Clinical Trial Update: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and tolerability of XmAb13676 (plamotamab) in CD20-expressing hematologic malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Plamotamab (plamotamab)

Snippet

Sponsor: Xencor, Inc. | Conditions: B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED